Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi e A. Lanzara, Second University of Naples, School of Medicine, Naples, Italy.
Cancer Invest. 2010 Oct;28(8):820-7. doi: 10.3109/07357901003630926.
We evaluated the association of a weekly cisplatin (35 mg/mq) and paclitaxel (45 mg/mq) regimen with radiotherapy (46 Gy) as primary treatment in locally advanced esophageal cancer (LAEC). The main end point was the activity in terms of pathologic complete response (pathCR) rate. Thirty-three LAEC patients received chemoradiation therapy during weeks 1-6 followed by esophagectomy. A pathCR was observed in 10/33 patients; 20/33 and 3/33 patients showed PR and SD, respectively. The EUS maximal transverse cross sectional area reduction >50% significantly correlated with pathCR. Three-year survival rate was 35%. These results support the activity and mild toxicity of this regimen.
我们评估了每周顺铂（35mg/mq）和紫杉醇（45mg/mq）联合放疗（46Gy）作为局部晚期食管癌（LAEC）的主要治疗方法。主要终点是病理完全缓解（pathCR）率的活性。33 例 LAEC 患者在第 1-6 周接受放化疗，然后进行食管切除术。10/33 例患者观察到 pathCR；20/33 例和 3/33 例患者分别显示 PR 和 SD。EUS 最大横截面积减少>50%与 pathCR 显著相关。3 年生存率为 35%。这些结果支持该方案的活性和轻度毒性。
